Search results
Author(s):
Jackson J Liang
,
Pasquale Santangeli
,
David J Callans
Added:
3 years ago
Ventricular tachycardia (VT) is a significant cause of morbidity and mortality in patients with structural heart disease (SHD). While implantable cardioverter-defibrillators (ICDs) have been shown to be effective in preventing sudden death due to ventricular arrhythmias, they are not able to prevent recurrent VT episodes. Antiarrhythmic drugs (AADs) have some demonstrated efficacy in preventing…
View more
Convergent AF Ablation
Author(s):
Karan Wats
,
Andy Kiser
,
Kevin Makati
,
et al
Added:
3 years ago
Article
Author(s):
David DeLurgio
,
Jaswinder Gill
,
Syed Ahsan
,
et al
Added:
2 years ago
Author(s):
Jorge E Romero
,
Dan L Li
,
Ricardo Avendano
,
et al
Added:
3 years ago
Brugada syndrome (BrS), one of the most common causes of sudden cardiac death (SCD) in normal structural heart individuals, is a young entity in modern medicine. BrS was first characterised in 1992 by Brugada et al. as a distinct syndrome with “right bundle branch block, persistent ST elevation in precordial leads V1 to V2–3 and sudden cardiac death”.1 The true prevalence of BrS is not clearly…
View more
Author(s):
Dhanunjaya Lakkireddy
Added:
2 years ago
In this interview, Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, Overland Park, KS, US) discusses the outcomes of the multicenter Susruta-IST Registry, which aimed to report upon the outcomes of sinus node sparing surgical thoracoscopic hybrid ablation (SUSRUTA) for inappropriate sinus tachycardia (IST).
Questions:
1. Please summarise the aim, study design and endpoints?
2. What…
View more
Author(s):
Carlo Pappone
Added:
11 months ago
EHRA 23 - We are joined onsite by Prof Carlo Pappone (IRCCS Policlinico San Donato, IT) who outlines the key findings of the BRUGADA Randomized trial.
In a randomized controlled trial, 150 patients with Brugada syndrome were enrolled in to develop an evidence-based treatment for the condition. Patients were randomized in a 2:1 fashion to receive either catheter ablation treatment with an ICD, or…
View more
Author(s):
Vincent Umbrain
,
Mark La Meir
,
Carlo de Asmundis
Added:
3 years ago
Dear Sir,
The question referring to the financial costs of one-stage hybrid surgery for atrial fibrillation in countries where reimbursement is limited is relevant in our modern cost–benefit driven society. But your question is out of the context of our manuscript as we never alluded to the financial aspects of the technique.
Costs for one-stage hybrid atrial fibrillation surgery are important…
View more
Author(s):
Georgios Giannopoulos
,
Spyridon Deftereos
Added:
3 years ago
Dear Sir,
We read with great interest the meta-analysis by Pearman et al.1 on the comparison between epicardial ablation for atrial fibrillation and the hybrid approach. The authors should be commended on the way they handled the data. The imbalance between the two meta-analytic cohorts – in terms of the type of atrial fibrillation and left atrial diameter – may have worked to the detriment of…
View more
Author(s):
Fouad Khalil
,
Konstantinos C Siontis
,
Gabor Bagameri
,
et al
Added:
3 years ago
Catheter-based ablation has been a well-established tool in the treatment of ventricular tachycardia (VT). However, the effectiveness of catheter ablation may be limited by its ability to access sites of arrhythmogenic tissue and achieve adequate lesion size in target areas without risking collateral damage. Antiarrhythmic surgery would be an effective alternative in such situations. Despite the…
View more
Author(s):
Mouhannad M Sadek
,
Robert D Schaller
,
Gregory E Supple
,
et al
Added:
3 years ago
Scar-related reentrant ventricular tachycardia (VT) may be present in a variety of structural heart disease (SHD) phenotypes. In this setting, VT circuits are comprised of viable myocytes separated by fibrosis, allowing for the slow conduction needed to facilitate reentry.1,2 Aetiologies of fibrosis include ischaemic heart disease (IHD), inflammatory conditions, infiltrative cardiomyopathy,…
View more